“I think he was the most brilliant person I’ve ever met," one long-time colleague said. 

The new analysis, presented during Heart Rhythm 2022, focused on patients treated at a high-volume facility during the COVID-19 pandemic. 

Heart Rhythm 2022, held from April 28 to May 1 in San Francisco, included a wide range of studies presented by some of the industry's leading specialists. 

Although current guidelines recommend radiologists evaluate CAC on all non-gated, non-contrast chest CT scans, the authors of the study note that these guidelines are not consistently followed.

The FDA’s approval was based on data from the EXPLORER-HCM trial, which showed that mavacamten was superior to a placebo for treating obstructive HCM and associated with no significant long-term, treatment-related adverse events.

The FDA and Medtronic warn some Heartware Ventricular Assist Device (HVAD) systems have a defect that may cause pump thrombosis.

New data from the STROKE AF clinical trial shows large and small vessel ischemic stroke patients who receive short-term or intermittent monitoring with Holter and 30-day external monitors had fewer AFib episodes detected that continuous implantable cardiac monitors.

The results of a study published in Radiology: Cardiothoracic Imaging call into question the value of initiating aspirin therapy in certain instances.

Researchers examined data from more than 750,000 heart failure hospitalizations, sharing their findings in JACC: Heart Failure. 

HeartFlow’s non-invasive cardiac computed tomography derived fractional flow reserve (FFR-CT) technology enables FFR values for the entire coronary tree of a patient using just a CT scan. This can show the significance of any coronary plaque lesions and if a patient needs to be sent to the cath lab for revascularization, or if they can be treated medically.